Astrotech Corporation — Form 10-Q Summary
Period clarification: The request identifies 2019 Q2, but the supplied filing is for the quarter and six months ended December 31, 2020 (Astrotech fiscal 2021 Q2). The filing is unaudited and was signed February 16, 2021.
Business context
Astrotech develops and commercializes mass spectrometry technology through subsidiaries. 1st Detect sells the TRACER 1000 explosives trace detector; AgLAB is developing agricultural analyzers; BreathTech is developing a breath-analysis product, including work with Cleveland Clinic on COVID-19 screening. TRACER 1000 had ECAC certification and more than $1 million in purchase orders plus $1 million in future service and support commitments, with DHL identified as its largest flagship customer. U.S. TSA cargo detection testing remained underway; passenger checkpoint certification testing was on indefinite hold.
Financial performance
| Metric ($ millions, except per-share data and margins) | Three months ended Dec. 31, 2020 | Prior-year quarter | Six months ended Dec. 31, 2020 | Prior-year six months |
|---|---|---|---|---|
| Revenue | 0.130 | 0.205 | 0.270 | 0.206 |
| Gross profit / margin | 0.002 / 2% | 0.009 / 4% | 0.029 / 11% | 0.010 / 5% |
| Operating expenses | 1.561 | 2.049 | 3.640 | 4.106 |
| Operating loss | (1.559) | (2.040) | (3.611) | (4.096) |
| Net loss | (1.622) | (2.083) | (3.733) | (4.151) |
| Basic and diluted loss per share | (0.10) | (0.35) | (0.32) | (0.72) |
| Operating cash flow | Not presented quarterly | (2.498) | (3.356) |
Quarterly revenue fell 37% year over year, attributed to order timing; all quarter revenue came from TRACER 1000 sales. Six-month revenue rose by $64,000. Management attributed lower operating expenses to reduced rent, travel, headcount-related costs, and R&D materials. Six-month results included a $544,000 corporate lease disposal charge; management said lease termination would save approximately $870,000 net cash over three years.
Balance sheet, funding and liquidity
- At December 31, 2020, cash and cash equivalents were $22.121 million, with $542,000 restricted cash; total cash and restricted cash were $22.663 million. Working capital was approximately $18.8 million, versus $0.3 million at June 30, 2020.
- Six-month operating cash use was $2.498 million; investing cash use was $16,000. Financing provided $21.828 million, primarily from common-stock offerings. The company ended the period with $18.810 million of stockholders’ equity, compared with $625,000 at June 30, 2020.
- Current and long-term term notes totaled approximately $3.042 million, including a $2.5 million related-party note balance. The CEO’s secured notes accrue interest at 11% and were extended to September 5, 2021. The $542,000 PPP loan was held in restricted cash pending forgiveness; SBA approval was not assured.
- October 2020 stock offerings generated approximately $24.2 million gross proceeds and $21.8 million net proceeds. Common shares outstanding rose from 7.85 million at June 30 to 18.54 million at December 31. The company also had 728,752 warrants outstanding at quarter-end.
- Astrotech said the offerings resolved the liquidity issue and that it no longer had substantial doubt about its ability to continue as a going concern. It also remained open to further financing, licensing, sale, merger, or strategic partnership options.
Outlook, risks and other notable items
- No quantified revenue, earnings, or cash-flow guidance is provided. Management expects gross margin could improve with higher production, volume discounts, and product refinements, but this is not a formal forecast.
- COVID-19 delayed TSA testing and parts of the supply chain and reduced near-term checkpoint demand. The company warned that further effects on operations, customers, liquidity, and results remain uncertain.
- One customer materially comprised essentially all revenue in both comparative periods, creating significant concentration risk. Deferred tax assets were fully offset by a valuation allowance; the effective tax rate was approximately 0%.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements. Disclosure controls were assessed as effective.
- After quarter-end, through February 9, the company sold 1,139,323 shares under its ATM program for approximately $3.5 million net. On February 11, it agreed to a further registered offering of 2,845,535 shares for approximately $9.25 million gross, plus placement-agent warrants.
Important facts for investors to verify
- Confirm the period: the supplied filing covers fiscal Q2 2021, not 2019 Q2.
- Track TSA cargo detection testing and whether TRACER 1000 earns U.S. approval, alongside the timing and conversion of disclosed orders and service commitments into revenue and cash.
- Assess cash burn against available cash, debt maturities and interest, PPP forgiveness status, and any subsequent financing needs.
- Evaluate dilution from the 2020 offerings, ATM sales, February 2021 offering, warrants, and any further share issuance.
- Monitor customer concentration, COVID-related operating impacts, and progress and costs for AgLAB and BreathTech development.